Across TCGA pan-cancer cohorts, SHISAL2B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SHISAL2B data layer compared with 23 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SHISAL2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SHISAL2B expression acts as an unfavorable survival marker.
LUAD are the cancer types where SHISAL2B mass-spec protein most reproducibly stratifies survival.